전체 프로그램

ADC 890 · Antibody 4071 · CGT 2714 · 다음 갱신 D-5 · 마지막 9월 2일

PopularRecently updatedCuratedMost trialsNeeds refreshORRLatestPhase 3FDA approved176 programs
CGTLimited DatastaleZhejiang Provincial People's Ho…Phase 2

NKG2D CAR-NK with PD-1 Antibody (NKG2D CAR-NK with PD-1 Antibody)

Anaplastic Throid Carcinoma · PD-1

#PD-1#CGT#Phase2#cell-gene-therapy#CAR-T+3
Trials 1Status Recruiting
CGTLimited DatastaleKAEDIPhase 1

NKG2D-based CAR T-cells (NKG2D-based CAR T-cells)

Hepatocellular Carcinoma; Glioblastoma · Hepatocellular Carcinoma

#HepatocellularCarcinoma#CGT#Phase1#cell-gene-therapy#CAR-T+3
Trials 1Status Active
CGTLimited DatastaleCelyad Oncology SAPhase 1

NKR-2 CAR-T Cells (NKR-2 CAR-T Cells)

AML, Adult; Myelodysplastic Syndromes · AML, Adult

#AMLAdult#CGT#Phase1#cell-gene-therapy#CAR-T+5
Trials 1Status Discontinued
CGTLimited DatastaleNkarta, Inc.Phase 1

NKX101 - CAR NK cell therapy (NKX101 - CAR NK cell therapy)

Relapsed/Refractory AML; AML, Adult · FRα

#FR#CGT#Phase1#cell-gene-therapy#CAR-T+5
Trials 1Status Recruiting
CGTLimited DatastaleThird Affiliated Hospital, Sun …Phase 1

Normal Dose NK cells ×4 times (Normal Dose NK cells ×4 times)

Hepatocellular Carcinoma · Hepatocellular Carcinoma

#HepatocellularCarcinoma#CGT#Phase1#cell-gene-therapy#CAR-T+2
Trials 1Status Active
CGTLimited DatastaleThird Affiliated Hospital, Sun …Phase 1

Normal Dose NK cells ×8 times (Normal Dose NK cells ×8 times)

Hepatocellular Carcinoma · Hepatocellular Carcinoma

#HepatocellularCarcinoma#CGT#Phase1#cell-gene-therapy#CAR-T+2
Trials 1Status Active
CGTLimited DatastaleM.D. Anderson Cancer CenterPhase 2

ONC-PluReceptor NK cells (ONC-PluReceptor NK cells)

Recurrent B-Cell Non-Hodgkin Lymphoma; Refractory B-cell Non-Hodgkin Lymphoma · FRα

#FR#CGT#Phase2#cell-gene-therapy#CAR-T+4
Trials 1Status Recruiting
CGTLimited Datastalejiuwei cuiPhase 1

PD-1-M1-NK Cells (PD-1-M1-NK Cells)

Advanced Gastric or Colorectal Cancer · PD-1

#PD-1#CGT#Phase1#cell-gene-therapy#CAR-T+3
Trials 1Status Recruiting
CGTLimited DatastaleMedigen Biotechnology Corporati…Phase 2

SLOG + Allogeneic NK cell (SLOG + Allogeneic NK cell)

Pancreatic Carcinoma Stage II; Cholangiocarcinoma Resectable · Pancreatic Carcinoma Stage II

#PancreaticCarcinomaStageII#CGT#Phase2#cell-gene-therapy#CAR-T+3
Trials 1Status Recruiting
CGTLimited DatastaleGuangdong ProCapZoom Bioscience…Preclinical

SZ003 CAR-NK (SZ003 CAR-NK)

Advanced Hepatocellular Carcinoma · Advanced Hepatocellular Carcinoma

#AdvancedHepatocellularCarcinoma#CGT#Preclinical#cell-gene-therapy#CAR-T+2
Trials 1Status Discontinued
AntibodyLimited DatastaleNektar TherapeuticsPhase 2

nivolumab (Opdivo, Schedule Finding Triplet: Combination of NKTR-214+ nivolumab+ ipilimumab)

Melanoma; Renal Cell Carcinoma · HER2

#HER2#Antibody#Phase2#monoclonal-antibody#Melanoma+2
Trials 1Status Active
CGTLimited DatastaleUniversidad Autonoma de MadridPhase 2

T memory cells and NK cells (T memory cells and NK cells)

Corona Virus Infection · Corona Virus Infection

#CoronaVirusInfection#CGT#Phase2#cell-gene-therapy#CAR-T+2
Trials 1Status Active
CGTLimited DatastaleM.D. Anderson Cancer CenterPhase 1

TGFBR-2 KO CD70 CAR NK (TGFBR-2 KO CD70 CAR NK)

Clear Cell Carcinoma; Phase 1 · Clear Cell Carcinoma

#ClearCellCarcinoma#CGT#Phase1#cell-gene-therapy#CAR-T+2
Trials 1Status Recruiting
CGTLimited DatastaleM.D. Anderson Cancer CenterPhase 1

TGFBR2 KO iC9/TROP2.CAR/IL-15 NK cells (TGFBR2 KO iC9/TROP2.CAR/IL-15 NK cells)

Breast Cancer · TROP2

#TROP2#CGT#Phase1#cell-gene-therapy#CAR-T+3
Trials 1Status Recruiting
AntibodyLimited DatastaleAbbVieApproved

infliximab, adalimumab, etanercept (TNF blockers, TNF blockers (infliximab, adalimumab, etanercept))

Arthritis, Rheumatoid; Spondylitis, Ankylosing · Arthritis, Rheumatoid

#ArthritisRheumatoid#Antibody#Approved#monoclonal-antibody#Arthritis+3
Trials 1Status Active
CGTLimited DatastaleBellicum Pharmaceuticals, Inc.Phase 1

TROP2-CAR-NK Cells (TROP2-CAR-NK Cells)

Colorectal Cancer; Minimal Residual Disease · TROP2

#TROP2#CGT#Phase1#cell-gene-therapy#CAR-T+4
Trials 1Status Recruiting
ADCLimited DatastaleDaiichi SankyoPreclinical

T-DXd, ENHERTU® (Trastuzumab Deruxtecan, Trastuzumab Deruxtecan (T-DXd, ENHERTU®))

Breast Cancer · Breast Cancer

#BreastCancer#ADC#Preclinical#antibody-drug-conjugate#Daiichi
Trials 1Status Recruiting
ADCLimited DatastaleDaiichi SankyoPhase 2

trastuzumab deruxtecan (Enhertu, T-DXd, DS-8201, Trastuzumab Deruxtecan and ivonescimab)

Breast Cancer · Breast Cancer

#BreastCancer#ADC#Phase2#antibody-drug-conjugate#Daiichi
Trials 1Status Recruiting
ADCLimited DatastaleDaiichi SankyoPhase 2

trastuzumab deruxtecan (Enhertu, T-DXd, DS-8201, Trastuzumab deruxtecan + FLO)

Esophagogastric Adenocarcinoma · Esophagogastric Adenocarcinoma

#EsophagogastricAdenocarcinoma#ADC#Phase2#antibody-drug-conjugate#Daiichi
Trials 1Status Recruiting
ADCLimited DatastaleDaiichi SankyoPhase 2

trastuzumab deruxtecan (Enhertu, T-DXd, DS-8201, Trastuzumab deruxtecan-nxki)

Breast Cancer; HER2-positive Breast Cancer · HER2

#HER2#ADC#Phase2#antibody-drug-conjugate#BreastCancer+2
Trials 1Status Recruiting

8 / 9 pages

← PreviousNext →